CLINICAL TRIAL RECRUITMENT FOR ABBV-744 STUDY FUNDAMENTALS EXPLAINED

In Phase A, individuals will acquire unique doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. More individuals will probably be enrolled in the recognized monotherapy dosign program. In Section B, participants will get oral ruxolitinib and ABBV-744 will likely be provided as "add-on" therapy. In Section C, members will